OSU BME Seminar Series: Dr. Mark Grinstaff, Boston University
In-person 2000 Fontana Labs
Mark Grinstaff, PhD
Department of Biomedical Engineering
"Clinically Informed Biomaterials: Chemistry and Engineering"
As an academic scientist and engineer working in interdisciplinary research, I ask questions all the time – from the most basic (how do we design small molecules to enable the synthesis of advanced materials?) to the most translational (how do we take a laboratory discovery to the clinic?). Through this process, I challenge my students and fellows to determine and elucidate the underlying chemistry and engineering principles. In this lecture, I will share our stories and successes in translating ideas from the laboratory to the preclinical and clinic setting. I begin with synthesis of unique dendrimers and dendritic-based hydrogels as adhesives for wound management, followed by the synthesis and use of polyglycerol carbonates for controlled drug delivery to prevent lung cancer recurrence, and, finally, ROMP to prepare large molecular weight polyanions as lubricants for cartilage surfaces and the potential treatment for osteoarthritis. In each section, I will highlight the design requirements, the synthetic routes and characterization data, and the performance outcomes in in vitro and in vivo experiments.
Mark W. Grinstaff is the William Fairfield Warren Distinguished Professor, the Distinguished Professor of Translational Research, and a Professor of Biomedical Engineering, Chemistry, Materials Science and Engineering, and Medicine at Boston University. He is also the Director of BU’s Nanotechnology Innovation Center, the Director of the NIH T32 Biomaterials Program, and the Associate Director for Engineering and Science at the BU Cancer Center. Mark's awards include the ACS Nobel Laureate Signature Award, NSF Career Award, Pew Scholar in the Biomedical Sciences, Camille Dreyfus Teacher-Scholar, Alfred P. Sloan Research Fellowship, the Edward M. Kennedy Award for Health Care Innovation, and the Clemson Award for Applied Research. He is a Fellow of the American Institute of Medical and Biological Engineering, the American Academy of Nanomedicine, the American Institute of Chemists, the Biomedical Engineering Society, the Royal Chemical Society, the Royal Society of Medicine, the International Academy of Medical and Biological Engineering, the American Association for the Advancement of Science and a Founding Fellow of the National Academy of Inventors. Over the course of his tenure, Grinstaff’s groundbreaking research has yielded more than 375 peer-reviewed publications, more than 200 patents and patent applications, and more than 325 oral presentations. His students and postdoctoral fellows have given more than 470 poster and 150 oral presentations at national and international conferences. His work has been cited more than 35,000 times. He is a co-founder of several companies and his innovative ideas and his efforts have also led to one new FDA approved pharmaceutical (AbraxaneTM) and four medical device products (OcuSeal® and Adherus Surgical Sealants®) that are now the standard of care. His current research activities involve the synthesis of new macromolecules and biomaterials, self-assembly chemistry, imaging contrast agents, drug delivery, and wound repair.